Skip to main content
Top
Published in: Drug Safety 7/2010

01-07-2010 | Original Research Article

Drugs Dispensed in Primary Care During Pregnancy

A Record-Linkage Analysis in Tayside, Scotland

Authors: Dr Linda Irvine, Robert W.V. Flynn, Gillian Libby, Iain K. Crombie, Josie M.M. Evans

Published in: Drug Safety | Issue 7/2010

Login to get access

Abstract

Background: For many regularly used drugs, evidence for safe use in pregnancy has not been established. Despite this, international studies have identified high levels of drug prescribing among pregnant women.
Objective: To investigate the patterns of prescribing of drugs to women who gave birth in Tayside, Scotland, in 2007.
Methods: Scottish maternity records were linked to dispensed prescribing data for all women who gave birth in Tayside in 2007. Drugs prescribed were coded according to the US FDA classification for risks of drugs in pregnancy. Patterns of prescribing were investigated during the 3 trimesters of pregnancy and the 3 months prior to conception.
Results: Prescribing in pregnancy was common, with 21 093 prescriptions dispensed to 3356 (85.2%) of the 3937 women. The most frequently prescribed drugs were antacids, antibacterials, oral iron, folic acid preparations and analgesics. Category A drugs (positive evidence of safety in pregnancy) and Category B drugs (some evidence of safety in pregnancy) accounted for 19.6% and 26.9% of all prescriptions dispensed, respectively. Prescribing of Category X drugs (evidence of risk to the fetus; use contraindicated in women who are or may become pregnant) during pregnancy was rare, with 112 prescriptions dispensed to 68 women (1.7%). Most of these were oral contraceptives or sex hormones. Prescribing of Category X drugs fell markedly during the first trimester and remained very low thereafter. Category D drugs (evidence of risk to the fetus but benefits of therapy may outweigh the potential risk) [432] were dispensed to 166 women (4.2%) during pregnancy. The most commonly prescribed Category D drugs were anxiolytics, nicotine replacement therapy and antiepileptic drugs. The frequency of prescribing of Category D drugs reduced in the third trimester. Prescribing of Category C drugs (insufficient evidence to know whether they are harmful) was common. Thirty percent of women received a total of 3641 Category C prescriptions, which accounted for 17.3% of all prescriptions issued during pregnancy. Prescribing of Category C drugs showed only a very modest decline during pregnancy. No FDA code was available for 4035 prescriptions issued (87 different items), the majority of which were for antacids and preparations for indigestion. More than 40% of women received such medications.
Conclusions: Prescribing of drugs during pregnancy was very common, but the levels of prescribing of drugs that are known to be harmful were low. Much of the prescribing was for drugs related to the pregnancy. While this study provides some evidence that primary-care prescribers in Tayside are prescribing potentially harmful drugs appropriately and with caution during pregnancy, safety data during pregnancy are unavailable for many drugs that are commonly prescribed.
Literature
1.
go back to reference Engeland A, Bramness JG, Daltveit AK, et al. Prescription drug use among fathers and mothers before and during pregnancy: a population-based cohort study of 106,000 pregnancies in Norway 2004–2006. Br J Clin Pharmacol 2008; 65: 653–60PubMedCrossRef Engeland A, Bramness JG, Daltveit AK, et al. Prescription drug use among fathers and mothers before and during pregnancy: a population-based cohort study of 106,000 pregnancies in Norway 2004–2006. Br J Clin Pharmacol 2008; 65: 653–60PubMedCrossRef
2.
go back to reference Gagne JJ, Maio V, Berghella V, et al. Prescription drug use during pregnancy: a population-based study in Regione Emilia-Romagna, Italy. Eur J Clin Pharmacol 2008; 64: 1125–32PubMedCrossRef Gagne JJ, Maio V, Berghella V, et al. Prescription drug use during pregnancy: a population-based study in Regione Emilia-Romagna, Italy. Eur J Clin Pharmacol 2008; 64: 1125–32PubMedCrossRef
3.
go back to reference Bakker MK, Jentink J, Vroom F, et al. Drug prescription patterns before, during and after pregnancy for chronic, occasional and pregnancy-related drugs in the Netherlands. BJOG 2006; 113: 559–68PubMedCrossRef Bakker MK, Jentink J, Vroom F, et al. Drug prescription patterns before, during and after pregnancy for chronic, occasional and pregnancy-related drugs in the Netherlands. BJOG 2006; 113: 559–68PubMedCrossRef
4.
go back to reference Riley EH, Fuentes-Afflick E, Jackson RA, et al. Correlates of prescription drug use during pregnancy. J Womens Health 2005; 14: 401–9CrossRef Riley EH, Fuentes-Afflick E, Jackson RA, et al. Correlates of prescription drug use during pregnancy. J Womens Health 2005; 14: 401–9CrossRef
5.
go back to reference Schirm E, Meijer WM, Tobi H, et al. Drug use by pregnant women and comparable non-pregnant women in the Netherlands with reference to the Australian classification system. Eur J Obstet Gynecol Reprod Biol 2004; 114: 182–8PubMedCrossRef Schirm E, Meijer WM, Tobi H, et al. Drug use by pregnant women and comparable non-pregnant women in the Netherlands with reference to the Australian classification system. Eur J Obstet Gynecol Reprod Biol 2004; 114: 182–8PubMedCrossRef
6.
go back to reference Andrade SE, Gurwitz JH, Davis RL, et al. Prescription drug use in pregnancy. Am J Obstet Gynecol 2004; 191: 398–407PubMedCrossRef Andrade SE, Gurwitz JH, Davis RL, et al. Prescription drug use in pregnancy. Am J Obstet Gynecol 2004; 191: 398–407PubMedCrossRef
7.
go back to reference Egen-Lappe V, Hasford J. Drug prescription in pregnancy: analysis of a large statutory sickness fund population. Eur J Clin Pharmacol 2004; 60: 659–66PubMedCrossRef Egen-Lappe V, Hasford J. Drug prescription in pregnancy: analysis of a large statutory sickness fund population. Eur J Clin Pharmacol 2004; 60: 659–66PubMedCrossRef
8.
go back to reference Lacroix I, Damase-Michel C, Lapeyre-Mestre M, et al. Prescription of drugs during pregnancy in France. Lancet 2000; 356: 1735–6PubMedCrossRef Lacroix I, Damase-Michel C, Lapeyre-Mestre M, et al. Prescription of drugs during pregnancy in France. Lancet 2000; 356: 1735–6PubMedCrossRef
9.
go back to reference Shehata HA, Nelson-Piercy C. Drugs in pregnancy: drugs to avoid. Best Pract Res Clin Obstet Gynaecol 2001; 15: 971–86PubMedCrossRef Shehata HA, Nelson-Piercy C. Drugs in pregnancy: drugs to avoid. Best Pract Res Clin Obstet Gynaecol 2001; 15: 971–86PubMedCrossRef
10.
go back to reference Koren G, Pastuszak A, Ito S. Drugs in pregnancy. N Engl J Med1998; 16: 1128–1 Koren G, Pastuszak A, Ito S. Drugs in pregnancy. N Engl J Med1998; 16: 1128–1
11.
go back to reference Little BB. Drugs and pregnancy: a handbook. London: Hodder Arnold, 2007 Little BB. Drugs and pregnancy: a handbook. London: Hodder Arnold, 2007
12.
go back to reference Webster WS, Freeman JA. Prescription drugs and pregnancy. Expert Opin Pharmacother 2003; 4: 949–61PubMedCrossRef Webster WS, Freeman JA. Prescription drugs and pregnancy. Expert Opin Pharmacother 2003; 4: 949–61PubMedCrossRef
13.
go back to reference Weiner CP, Buhimschi C, Swaan P. Drug-prescribing challenges during pregnancy. Curr Obstet Gynaecol 2005; 15: 157–65CrossRef Weiner CP, Buhimschi C, Swaan P. Drug-prescribing challenges during pregnancy. Curr Obstet Gynaecol 2005; 15: 157–65CrossRef
14.
go back to reference Mitchell AA. Systematic identification of drugs that cause birth defects: a new opportunity. N Engl J Med 2003; 349: 2556–9PubMedCrossRef Mitchell AA. Systematic identification of drugs that cause birth defects: a new opportunity. N Engl J Med 2003; 349: 2556–9PubMedCrossRef
15.
go back to reference Evans JMM, McDevitt DG, MacDonald TM. The Tayside Medicines Monitoring Unit (MEMO): a record-linkage system for pharmacovigilance. Pharmaceut Med 1995; 9: 177–84 Evans JMM, McDevitt DG, MacDonald TM. The Tayside Medicines Monitoring Unit (MEMO): a record-linkage system for pharmacovigilance. Pharmaceut Med 1995; 9: 177–84
16.
go back to reference British National Formulary. London: BMJ Group and RPS Publishing, 2007 British National Formulary. London: BMJ Group and RPS Publishing, 2007
19.
go back to reference Department of Health and Human Services, Food and Drug Administration. Content and format of labeling for human prescription drug and biological products; requirements for pregnancy and lactation labeling. Fed Regist 2008; 73: 30831–68 Department of Health and Human Services, Food and Drug Administration. Content and format of labeling for human prescription drug and biological products; requirements for pregnancy and lactation labeling. Fed Regist 2008; 73: 30831–68
20.
go back to reference Colvin L, Slack-Smith L, Stanley FJ, et al. Pharmacovigilance in pregnancy using population-based linked data-sets. Pharmacoepidemiol Drug Saf 2009; 18: 211–25PubMedCrossRef Colvin L, Slack-Smith L, Stanley FJ, et al. Pharmacovigilance in pregnancy using population-based linked data-sets. Pharmacoepidemiol Drug Saf 2009; 18: 211–25PubMedCrossRef
21.
go back to reference Briggs GG, Freeman RK, Yaffe SJ. Drugs in pregnancy and lactation: a reference guide to fetal and neonatal risk. 7th ed. Philadelphia (PA): Lippincott, Williams and Wilkins, 2005 Briggs GG, Freeman RK, Yaffe SJ. Drugs in pregnancy and lactation: a reference guide to fetal and neonatal risk. 7th ed. Philadelphia (PA): Lippincott, Williams and Wilkins, 2005
22.
go back to reference Physicians’ desk reference. 58th ed. Montvale (NJ): Thomson PDR, 2004 Physicians’ desk reference. 58th ed. Montvale (NJ): Thomson PDR, 2004
23.
go back to reference Spratto GR, Woods AL. PDR nurse’s drug handbook. Montvale (NJ): Thomson PDR, 2006 Spratto GR, Woods AL. PDR nurse’s drug handbook. Montvale (NJ): Thomson PDR, 2006
25.
go back to reference Lee E, Maneno MK, Smith L, et al. National patterns of medication use during pregnancy. Pharmacoepidemiol Drug Saf 2006; 15: 537–45PubMedCrossRef Lee E, Maneno MK, Smith L, et al. National patterns of medication use during pregnancy. Pharmacoepidemiol Drug Saf 2006; 15: 537–45PubMedCrossRef
26.
go back to reference Wen SW, Yang T, Krewski D, et al. Patterns of pregnancy exposure to prescription FDA C, D and X drugs in a Canadian population. J Perinatol 2008; 28: 324–9PubMedCrossRef Wen SW, Yang T, Krewski D, et al. Patterns of pregnancy exposure to prescription FDA C, D and X drugs in a Canadian population. J Perinatol 2008; 28: 324–9PubMedCrossRef
27.
go back to reference Andrade SE, Raebel MA, Morse AN, et al. Use of prescription medications with a potential for fetal harm among pregnant women. Pharmacoepidemiol Drug Saf 2006; 15: 546–54PubMedCrossRef Andrade SE, Raebel MA, Morse AN, et al. Use of prescription medications with a potential for fetal harm among pregnant women. Pharmacoepidemiol Drug Saf 2006; 15: 546–54PubMedCrossRef
28.
go back to reference Cooper WO, Hickson GB, Ray WA. Prescriptions for con-traindicated category X drugs in pregnancy among women enrolled in TennCare. Paediatr Perinat Epidemiol 2004; 18: 106–11PubMedCrossRef Cooper WO, Hickson GB, Ray WA. Prescriptions for con-traindicated category X drugs in pregnancy among women enrolled in TennCare. Paediatr Perinat Epidemiol 2004; 18: 106–11PubMedCrossRef
29.
go back to reference Hardy JR, Leaderer BP, Holford TR, et al. Safety of medications prescribed before and during early pregnancy in a cohort of 81,975 mothers from the UK General Practice Research Database. Pharmacoepidemiol Drug Saf 2006; 15: 555–64PubMedCrossRef Hardy JR, Leaderer BP, Holford TR, et al. Safety of medications prescribed before and during early pregnancy in a cohort of 81,975 mothers from the UK General Practice Research Database. Pharmacoepidemiol Drug Saf 2006; 15: 555–64PubMedCrossRef
30.
go back to reference Malm H, Martikainen J, Klaukka T, et al. Prescription of hazardous drugs during pregnancy. Drug Saf 2004; 27: 899–908PubMedCrossRef Malm H, Martikainen J, Klaukka T, et al. Prescription of hazardous drugs during pregnancy. Drug Saf 2004; 27: 899–908PubMedCrossRef
31.
go back to reference Olesen C, Sørensen HT, de Jong-van den Berg L, et al. Prescribing during pregnancy and lactation with reference to the Swedish classification system: a population-based study among Danish women. Acta Obstet Gynecol Scand 1999; 78: 686–92PubMedCrossRef Olesen C, Sørensen HT, de Jong-van den Berg L, et al. Prescribing during pregnancy and lactation with reference to the Swedish classification system: a population-based study among Danish women. Acta Obstet Gynecol Scand 1999; 78: 686–92PubMedCrossRef
32.
go back to reference De Vigan C, De Walle HE, Cordier S, et al. Therapeutic drug use during pregnancy: a comparison in four European countries. OECM Working Group. Occupational Exposures and Congenital Anomalies. J Clin Epidemiol 1999; 52: 977–82PubMedCrossRef De Vigan C, De Walle HE, Cordier S, et al. Therapeutic drug use during pregnancy: a comparison in four European countries. OECM Working Group. Occupational Exposures and Congenital Anomalies. J Clin Epidemiol 1999; 52: 977–82PubMedCrossRef
34.
go back to reference Haramburu F, Miremont-Salamé G, Moore N. Good and bad drug prescription in pregnancy. Lancet 2000; 356: 1704PubMedCrossRef Haramburu F, Miremont-Salamé G, Moore N. Good and bad drug prescription in pregnancy. Lancet 2000; 356: 1704PubMedCrossRef
Metadata
Title
Drugs Dispensed in Primary Care During Pregnancy
A Record-Linkage Analysis in Tayside, Scotland
Authors
Dr Linda Irvine
Robert W.V. Flynn
Gillian Libby
Iain K. Crombie
Josie M.M. Evans
Publication date
01-07-2010
Publisher
Springer International Publishing
Published in
Drug Safety / Issue 7/2010
Print ISSN: 0114-5916
Electronic ISSN: 1179-1942
DOI
https://doi.org/10.2165/11532330-000000000-00000

Other articles of this Issue 7/2010

Drug Safety 7/2010 Go to the issue

Review Article

Amiodarone